A vaccine must be widely tested in humans before being administered to hundreds of millions, say experts
More than 133 million shares of HUL were sold in the Rs 1,900-1,950 range, via multiple large transactions in morning trade
Over 133 million shares, or 5.7% of the paid-up capital, are being offered for Rs 1,850-1,950 to investors through a special block window
The firm may offload part or all of its 5.7% holding in HUL through a series of block trades
The drugmakers said they expect to start clinical trials for the vaccine in the second half of this year.
The merger will also give HUL access to brands such as Horlicks and Boost, pitting the company against rivals such as Nestle India, another big player in the health and nutrition segment.
The NCLT nod paves the way for the final leg of the merger process, including an announcement of the record date (of the merger) and share allotment
The firm's operating revenue stood at Rs 1,159 crore - up 3.7 per cent YoY from Rs 1,117 crore
STEER which was founded in 1993 by Padmanabhan has 5 global offices and 10 satellite offices, serving over 39 countries. It employs over 500 engineers, scientists and technicians across the globe
The Prime Minister's Office is considering the proposal and a decision is expected soon
According to the company, its domestic business grew 7 per cent, backed by Horlicks' and Boost's performance
Indian drugmakers have also started testing their ranitidine products at various laboratories after the US FDA issued an advisory on the drug to health care professionals
According to the firm's FY19 annual report, it fetched Rs 5 crore during the year from the sale of brands
Bharat Biotech chairman Krishna Ella said the acquisition of Chiron Behring would make the company world's largest producer of anti-rabies vaccine
Ruling out any impact on GSK's India business, company sources said in India the pharma entity owned and manufactured products such as Iodex and Ostocalcium, which were marketed by GSK Consumer
Tesaro boosts GSK's pharma portfolio at high price $75/ share; cash from Horlicks sale to help fund pharma investment
The company is assessing its 72.5 per cent holding in India-listed GlaxoSmithKline Consumer Healthcare Ltd. as part of that process
Some investors have long called for the group's break-up, arguing that it would crystallise value for component businesses